申请人:SHENZHEN SALUBRIS PHARM CO LTD
公开号:US10513514B2
公开(公告)日:2019-12-24
One aspect of the invention relates to a series of new PCSK9 inhibitor compounds comprising piperidine ring structures, including compounds of formula (I) and/or pharmaceutically acceptable salts thereof. Another aspect of the invention relates to methods of treating PCSK9 receptor related diseases comprising administration of one or more compounds of formula (I) or a pharmaceutically acceptable salt thereof.
本发明的一个方面涉及一系列新的包含哌啶环结构的PCSK9抑制剂化合物,包括式(I)化合物和/或其药学上可接受的盐。本发明的另一方面涉及治疗 PCSK9 受体相关疾病的方法,包括施用一种或多种式(I)化合物或其药学上可接受的盐。